← Leaderboards
Kathy J Helzlsouer
Johns Hopkins University
$7,655,009
Attributed
$7,655,009
Total exposure
9
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$7,655,009 · 9
By mechanism
U01$6,409,204 · 2
T32$939,448 · 1
R03$294,449 · 2
M01$11,908 · 3
P50$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Craig A Townsend$23,597,395
- Dale Murray Needham$11,296,966
- Francis M Giardiello$6,524,423
- Edward W. Gabrielson$7,965,645
- Stephen B Baylin$40,109,757
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectCancer RiskBreast NeoplasmsFemaleNeoplasm /Cancer GeneticsGenetic PolymorphismWomen'S HealthCooperative StudyNeoplasm /Cancer EpidemiologyNeoplasm /Cancer DiagnosisEarly DiagnosisDna RepairHormone MetabolismBiomarkerLung NeoplasmsCarcinogenesisCancer Registry /ResourceFatty Acid SynthaseHuman TissueAdductGenetic SusceptibilityHemoglobinInsulinlike Growth Factor
Grant awards (23)
CLUE STUDIES--EVALUATING BIOMARKERS OF CARCINOGENESIS$930,585
U01 · FY2004 · CA
Reliability of Ductal Lavage$8,931
M01 · FY2004 · RR
MACGN$2,977
M01 · FY2004 · RR
CLUE STUDIES--EVALUATING BIOMARKERS OF CARCINOGENESIS$897,895
U01 · FY2003 · CA
Androgens, Growth Factors, and Ovarian Cancer$74,476
R03 · FY2003 · CA
CLUE STUDIES--EVALUATING BIOMARKERS OF CARCINOGENESIS$847,363
U01 · FY2002 · CA
GENE-ENVIRONMENT INTERACTIONS: THE ODYSSEY COHORT$587,315
U01 · FY2002 · AG
INSTITUTIONAL RESEARCH CANCER EPIDEMIOLOGY FELLOWSHIP$369,429
T32 · FY2002 · CA
Androgens, Growth Factors, and Ovarian Cancer$66,947
R03 · FY2002 · CA
MOLECULAR EPIDEMIOLOGY OF PROGRESSION TO BREAST CANCER$0
P50 · FY2002 · CA
CLINICAL TRIAL TO DETERMINE WORTH OF TAMOXIFEN FOR BREAST CANCER PREVENTION$0
M01 · FY2002 · RR
CLUE STUDIES--EVALUATING BIOMARKERS OF CARCINOGENESIS$865,161
U01 · FY2001 · CA
GENE-ENVIRONMENT INTERACTIONS: THE ODYSSEY COHORT$804,644
U01 · FY2001 · AG
INSTITUTIONAL RESEARCH CANCER EPIDEMIOLOGY FELLOWSHIP$255,259
T32 · FY2001 · CA
EPIDEMIOLOGY OF PROSTATE CANCER--ODC AND AR GENOTYPES$76,032
R03 · FY2001 · CA
MOLECULAR EPIDEMIOLOGY OF PROGRESSION TO BREAST CANCER$0
P50 · FY2001 · CA
CLINICAL TRIAL TO DETERMINE WORTH OF TAMOXIFEN FOR BREAST CANCER PREVENTION$0
M01 · FY2001 · RR
GENE-ENVIRONMENT INTERACTIONS: THE ODYSSEY COHORT$776,242
U01 · FY2000 · AG
CLUE STUDIES--EVALUATING BIOMARKERS OF CARCINOGENESIS$699,999
U01 · FY2000 · CA
INSTITUTIONAL RESEARCH CANCER EPIDEMIOLOGY FELLOWSHIP$314,760
T32 · FY2000 · CA
EPIDEMIOLOGY OF PROSTATE CANCER--ODC AND AR GENOTYPES$76,994
R03 · FY2000 · CA
MOLECULAR EPIDEMIOLOGY OF PROGRESSION TO BREAST CANCER$0
P50 · FY2000 · CA
CLINICAL TRIAL TO DETERMINE WORTH OF TAMOXIFEN FOR BREAST CANCER PREVENTION$0
M01 · FY2000 · RR